pharmaphorum April 26, 2022
Abbott has revamped the digital health app used alongside its neurostimulation devices for chronic pain, making it easier for doctors to track how well patients are managing the treatment.
The Neurosphere myPath app is designed to track and report on patient-perceived pain relief and general well-being associated with spinal cord stimulation (SCS) or dorsal root ganglion (DRG) therapy using Abbott’s Proclaim device range.
First launched in January 2021, the tool is used during a trial period before the neurostimulation devices are implanted to make sure that patients are responding to the treatment.
During the trial, temporary leads are placed and connected to an external generator, allowing patients to experience first-hand the impact of neuromodulation on their chronic pain and related...
Today's Sponsors
Today's Sponsor